Small team, big need Mati Therapeutics is a tiny company with 0-1 employees and a focused platform in punctal plug drug delivery for the eye. This indicates a potential early-stage partner with high appetite for strategic collaborations, licensing opportunities, or early-access programs for their PPDS technology.

Clinical focus Their technology targets glaucoma and ocular hypertension with plans to explore anti-inflammatory and dry eye applications. Sales conversations can emphasize ophthalmology product development partnerships, distribution deals with eye care device manufacturers, or joint ventures to co-develop drug-eluting punctal plugs.

Funding traction With modest funding of around $1.6 million and revenue under $1 million, Mati may be seeking strategic investors or collaborators to scale manufacturing, regulatory pathways, and clinical trials. Opportunity exists to propose co-development funding, milestone-based partnerships, or tech licensing.

Leadership signal Leadership changes include a recent COO appointment, signaling a move toward operational scale. This presents a window to engage in conversations about supply chain setup, contract manufacturing, clinical operations support, and go-to-market strategy consulting for ophthalmic products.

Market positioning As a niche ocular drug-delivery platform with potential expansion to steroids, NSAIDs, dry eye, and allergies, Mati could leverage partnerships with established ophthalmology players to access distribution networks, KOL ecosystems, and payer strategies for novel, minimally invasive treatments.